New Drug-Radiation combo aims to spare bladders in cancer patients
NCT ID NCT05833867
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This early-phase trial tests whether combining the drug sacituzumab govitecan with advanced radiation therapy is safe and tolerable for people with muscle-invasive bladder cancer that hasn't spread. The goal is to treat the cancer while preserving the bladder, avoiding surgical removal. About 20 participants will receive the drug intravenously before and during radiation, with follow-up for up to 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New strategy aims to eliminate residual bladder cancer after drug combo
- Keytruda may let some bladder cancer patients avoid bladder removal
- Scientists hunt for clues in bladder Cancer's surrounding tissue
- New radiation technique aims to slash gut damage in bladder cancer patients
- Bladder cancer drug trial halted early after enrolling just 4 patients
- New Bladder-Sparing combo could change how we treat aggressive bladder cancer